Clinical value of urine nuclear matrix protein 22 (NMP22) quantitative test in the diagnosis of bladder cancer in a schistosoma endemic region

Authors

  • Oyibo Ugbede Emmanuel Urology unit, Department of Surgery, Usmanu Danfodiyo University Teaching Hospital, Sokoto, Sokoto State, Nigeria
  • Abubakar Sadiq Muhammad Urology unit, Department of Surgery, Usmanu Danfodiyo University Teaching Hospital, Sokoto, Sokoto State, Nigeria
  • Ngwobia Peter Agwu Urology unit, Department of Surgery, Usmanu Danfodiyo University Teaching Hospital, Sokoto, Sokoto State, Nigeria
  • Abdullahi Abdulwahab-Ahmed Urology unit, Department of Surgery, Usmanu Danfodiyo University Teaching Hospital, Sokoto, Sokoto State, Nigeria
  • Mungadi Ismaila Arzika Urology unit, Department of Surgery, Usmanu Danfodiyo University Teaching Hospital, Sokoto, Sokoto State, Nigeria Institute of Urology and Nephrology, Usmanu Danfodiyo University Sokoto, Sokoto State, Nigeria

DOI:

https://doi.org/10.18203/2349-2902.isj20222591

Keywords:

Bladder cancer, Clinical value, Diagnosis, Nuclear matrix protein 22

Abstract

Background: Bladder cancer is the ninth commonest cancer and the 13th most common cause of mortality worldwide. Its early diagnosis poses a great challenge therefore the need to identify biomarkers which may improve the current diagnostic practice.

Methods: This is a prospective study of patients managed for bladder cancer at the urology unit, department of surgery, Usmanu Danfodiyo University Teaching Hospital, Sokoto, Nigeria between April 2019 to June 2020. Urine cytology, urine nuclear matrix protein 22 (NMP22) quantitative test and histology of the bladder biopsy specimens were done at the Histopathology and Chemical Pathology laboratory respectively of the Usmanu Danfodiyo University Teaching Hospital, Sokoto. Data was collected using a structured proforma and analyzed using statistical package for social sciences (SPSS) version 20.0.

Results: Eighty-three patients enrolled in the study however 46 of them with features of bladder carcinoma participating in the study group and 37 in the control group. The study and control groups' mean age and age range are (49.70±11.45,18-69) and (51.84±13.75,18-78) years, respectively. The sensitivity, specificity, PPV, NPV and AUC of urine NMP22 and urine cytology in the study were (78.3% vs. 58.7%), (32.4% vs. 100.0%), (59.0% vs. 100.0%), (54.6% vs. 66.1%), (0.207 vs. 0.538) respectively for the diagnosis of bladder cancer.

Conclusions: Urine NMP22 quantitative test shows high sensitivity, low specificity and a low AUC compared to urine cytology and thus of poor clinical value in the diagnosis of bladder cancer in our region.

Author Biography

Oyibo Ugbede Emmanuel, Urology unit, Department of Surgery, Usmanu Danfodiyo University Teaching Hospital, Sokoto, Sokoto State, Nigeria

UROLOGY UNIT

DEPARTMENT OF SURGERY

USMANU DANFODIYO UNIVERSITY TEACHING HOSPITAL SOKOTO.SOKOTO STATE.NIGERIA.

CONSULTANT

References

Parkin DM. The global burden of urinary bladder cancer. Scand J Urol Nephrol. 2008;42:12-20.

David PW. Urothelial tumours of the bladder. In: Wein AJ, Kavoussi LR, Partin AW, Peters CA, eds. Campbell-Walsh Urology. 11th ed. Philadelphia: Saunders Elsevier Inc; 2015:2184-204.

Sahabi SM, Abdullahi K. Epidemiological survey of malignant neoplasms in Sokoto, Nigeria. World J Res Rev. 2017;4:10-15.

Mungadi IA, Malami SA. Urinary bladder cancer and schistosomiasis in North-Western Nigeria. West Afr J Med. 2007;26:226-9.

Sullivan PS, Chan JB, Levin MR, Rao J. Urine cytology and adjunct markers for detection and surveillance of bladder cancer. Am J Translat Res. 2010;2:412-40.

Muhammad AS, Mungadi IA, Ndodu ED, Kalayi GD. Performance of urinary survivin as a non-invasive molecular marker of bladder carcinoma in a schistosomiasis endemic area. Ghana Med J. 2018;52:74-8.

Kirsten LG, Badrinath K. Urinary markers for bladder cancer. AUA Update Series. 2007;26:326-35.

Ahn JS, Kim H-S, Chang S-G, Jeon SH. The clinical usefulness of nuclear matrix protein-22 in patients with atypical urine cytology. Korean J Urol. 2011;52:603-6.

Ibrahim M. Research Methodology and Dissertation writing for Health and Allied Health Professionals. 1st ed. Abuja, Nigeria: Cress Global Link Limited; 2009:74-5.

Malami SA, Pindiga UH, Abimiku BA, Mungadi IA, Abdullahi AD, Dauda A, et al. A Descriptive retrospective study of the pattern of malignant diseases in Sokoto, North Western Nigeria (1999-2004). J Med Sci. 2007;7:1033-8.

Muhammad AS, Mungadi IA, Darlington NN, Kalayi GD. Effectiveness of bladder tumor antigen quantitative test in the diagnosis of bladder carcinoma in a schistosoma endemic area. Urol Ann. 2019;11:143-8.

Rambau PF, Chalya PL, Jackson K. Schistosomiasis and urinary bladder cancer in North Western Tanzania: a retrospective review of 185 patients. Infect Agent Cancer. 2013;8:1-6.

Singh K, Muddasiru D. Epidemiology of schistosomiasis in school aged children in some riverine areas of Sokoto, Nigeria. J Public Health Epidemiol. 2014;8:197-201.

Bala AY, Ladan MU, Mainasara M. Prevalence and intensity of urinary schistosomiasis in Abarma village, Gusau, Nigeria: A preliminary investigation. Sci World J. 2012;7:1-4.

Shariat SF, Sfakianos JP, Droller MJ, Karakiewicz PI, Meryn S, Bochner BH. The effect of age and gender on bladder cancer: a critical review of the literature. Br J Urol Int. 2010;105:300-8.

Gupta P, Jain M, Kapoor R, Muruganandham K, Srivastava A, Mandhani A. Impact of age and gender on the clinicopathological characteristics of bladder cancer. Indian J Urol. 2009;25:207-10.

Akogun OB. Urinary Schistosomiasis and the Coming of Age in Nigeria. Parasitol Today. 1991;7:62-73.

Ochicha O, Alhassan S, Mohammed AZ, Edino ST, Nwokedi EE. Bladder cancer in Kano-a histopathological review. West African J Med. 2003;22:202-4.

Bowa K, Mulele C, Kachimba J, Manda E, Mapulanga V, Mukosai S. A review of bladder cancer in sub-saharan Africa: a different disease, with a distinct presentation, assessment, and treatment. Ann Afr Med. 2018;17:99-105.

Caraway NP, Katz RL. A review on the current state of urine cytology emphasizing the role of fluorescence in situ hybridization as an adjunct to diagnosis. Cancer Cytopathol. 2010;118:175-83.

Riadh BSM, El Atat R, Sfaxi M, Derouiche A, Kourda N, Chebil M. Clinical presentation and outcome of bladder schistosoma-unrelated squamous cell carcinoma: report on 33 consecutive cases. Clin Genitourinary Cancer. 2007;5:409-12.

Shaaban AA, Orkubi SA, Said MT, Yousef B, Abomelha MS. Squamous cell carcinoma of the urinary bladder. Ann Saudi Med. 1997;17:115-9.

Zippe C, Pandrangi L, Agarwal A. NMP22 is a sensitive,cost-effective test in patients at risk for bladder cancer. J Urol. 1999;161:62-5.

Kumar A, Kumar R, Gupta NP. Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer. Japanese J Clin Oncol. 2006;36:172-5.

Salama RHM, Selem TH, El-Gammal M, Elhagagy AA, Bakar SM. Urinary Tumor Markers Could Predict Survival in Bladder Carcinoma. Indian J Clin Biochem. 2013;28:265-71.

Akaza H, Miyanaga N, Tsukamoto T, Ishikawa S, Noguchi R, Ohtani M, et al. Evaluation of urinary NMP22 (nuclear matrix protein 22 as a diagnostic marker for urothelial cancer--NMP22 as a urinary marker for surveillance of bladder cancer. Cancer Chemother. 1997;24:829-36.

Horstmann M, Todenhöfer T, Hennenlotter J, Aufderklamm S, Mischinger J, Kuehs U, et al. Influence of age on false positive rates of urine-based tumor markers. World J Urol. 2013;31:935-40.

Volpe A, Racioppi M, D’agostino D, Cappa E, Gardi M, Totaro A, et al. Bladder tumor markers: a review of the literature. Int J Biol Markers. 2008;23:249-61.

Casetta G, Gontero P, Zitella A, Pelucelli G, Formiconi A, Priolo G, et al. BTA Quantitative Assay and NMP22 Testing Compared with Urine Cytology in the Detection of Transitional Cell Carcinoma of the Bladder. Urol Int. 2000;65:100-5.

Ketat A, Diab I, Dwidar F, Sameh W. Evaluation of tissue and urinary survivin expression in non-muscle-invasive bladder cancer. Afr J Urol. 2012;18:143-8.

Abdelgawad I, Moussa H, Nasr M, Gemae E, Masooud A, Ibrahim K, et al. Comparative Study of NMP22, Telomerase, and BTA in the Detection of Bladder Cancer. J Egyptian Nat Cancer Inst. 2005;17:193-202.

Lekili M, Sener E, Demir MA, Temeltaş G, Müezzinoğlu T, Büyüksu C. Comparison of the nuclear matrix protein 22 with voided urine cytology in the diagnosis of transitional cell carcinoma of the bladder. Urol Res. 2004;32:124-8.

Chawla N, Mehta R, Tewari K. Role of urine cytology in bladder neoplasm- Cytopathological correlation and review of literature. J Marine Med Soc. 2018;20:27-30.

Brimo F, Vollmer RT, Case B, Aprikian A, Kassouf W, Auger M. Accuracy of urine cytology and the significance of an atypical category. Am J Clin Pathol. 2009;132:785-93.

Mansoor I. Analysis of urine cytology at a community hospital. J Ayub Med Coll Abbottabad. 2003;15:20-3.

Raab SS, Grzybicki DM, Vrbin CM, Geisinger KR. Urine cytology discrepancies: frequency, causes, and outcomes. Am J Clin Pathol. 2007;127:946-53.

Abdulwahab-Ahmed A, Umar AM, Onwuasoanya UE, Oyibo EU, Dahiru A, Mungadi IA. The pattern of urine cytology among patients with clinical diagnosis of bladder tumor in a tertiary hospital northwest Nigeria. Int Surg J. 2019;6:3521-4

El-Bolkainy MN, Ghoneim MA, El-Horsey A, Nasir SM.Carcinoma of Bilharzial bladder: diagnostic value of urine cytology. Urology. 1974;3(3):319-23.

El Sebai I. Cancer of the bladder in Egypt. Kasr-El-Aini J Surg. 1961;2:183-241.

Klufio GD, Mensah JE. Bladder, urethra and penis. In: Badoe EA, Archampong EQ, da Rocha Afodu JT, eds. Principles and practice of surgery including pathology in the tropics. 4th ed. Accra: Ghana Publishing Company; 2015:925-30.

Alhasan SU, Abdullahi A, Sheshe AA, Mohammed AZ, Edino ST, Aji SA. Radical Cystectomy for Locally Advanced Carcinoma of the Bladder in Kano, Nigeria. Afr J Urol. 2007;13:112-8.

Downloads

Published

2022-09-28

Issue

Section

Original Research Articles